This report was first published by Endpoints News. To see the original version, click here
In January, Revolution Medicines was rumored to have a $30 billion buyout offer on the table. Now, it doesn’t.
Also in January, Revolution didn’t have its Phase 3 pancreatic cancer results. Now, it does.
您已阅读5%（292字），剩余95%（6043字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。